DXSE:XETRA:XETRA-Xtrackers - Stoxx Europe 600 Health Care Swap UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 226.3

Change

+0.60 (+0.27)%

Market Cap

USD 0.14B

Volume

7.63K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.80 (-1.54%)

USD 426.26B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.33 (-1.97%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.13 (-0.46%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.13 (-0.44%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.23 (-0.93%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.23 (-0.49%)

USD 104.42B
8R80:XETRA Amundi Index Solutions - Amund..

-0.86 (-0.60%)

USD 104.42B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.28 (-0.54%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.39 (+0.37%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+2.70 (+0.45%)

USD 80.38B

ETFs Containing DXSE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.93% 55% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.93% 54% F 56% F
Trailing 12 Months  
Capital Gain 15.87% 59% D- 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.87% 58% F 59% D-
Trailing 5 Years  
Capital Gain 46.95% 72% C 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.95% 70% C- 69% C-
Average Annual (5 Year Horizon)  
Capital Gain 9.41% 66% D+ 65% D
Dividend Return 9.41% 65% D 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.75% 66% D+ 73% C
Risk Adjusted Return 107.56% 97% N/A 97% N/A
Market Capitalization 0.14B 39% F 35% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.